In The News Posted April 17, 2019 Share Posted April 17, 2019 MILL VALLEY, Calif. and MELBOURNE, Australia, April 17, 2019 /PRNewswire/ -- The Background In 2016, FightMND helped to support the phase 1 clinical trial of CuATSM where it was given to MND patients as a therapeutic for the first time. The primary objective, as per any phase 1 trial, was ... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.